This medicine is now known as nalfurafine.
On 11 September 2002, orphan designation (EU/3/02/115) was granted by the European Commission to Toray Europe Limited, United Kingdom, for (-)-17-(cyclopropylmethyl)-3,14 ß-dihydroxy-4,5 α-epoxy-6ß-[N-methyl-trans-3-(3-furyl) acrylamido] morphinan hydrochloride (intravenous use) for the treatment of uremic pruritus.
Toray Europe Limited changed name to Toray International U.K. Limited in January 2008.
The sponsorship was transferred to Toray International Europe GmbH, Germany, in February 2017.
EU/3/02/115: Public summary of positive opinion for orphan designation of (-)-17-(cyclopropylmethyl)-3,14 àŸ-dihydroxy-4,5 Î±-epoxy-6àŸ-[N-methyl-trans-3-(3-furyl) acrylamido] morphinan hydrochloride (intravenous use) fo... (PDF/102.02 KB)
First published: 09/02/2009
Last updated: 18/11/2010
(-)-17(Cyclopropylmethyl)-1,14 beta-dihydroxy-4,5 alpha-epoxy-6beta-[N-methyl-trans-3-(3-furyl) acrylamido] morphinan hydrochloride (nalfurafine)
|Disease / condition||
Treatment of uraemic pruritus
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;